Hospital

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to those of younger patients.

AI is reshaping pharmacy, from catching dangerous drug interactions to personalizing chemotherapy dosing.

Review finds prior authorizations delay neurologic treatment, trigger relapses, and intensify clinician burnout, spurring calls for rapid reform.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Pharmacy supply chain disruptions directly shape the treatment that patients receive, making it vital that pharmacists understand the causes and consequences of delays.

Joseph Saseen, PharmD, addresses statin intolerance and misinformation and provides a look at aggressive new LDL targets and emerging therapies not yet captured in the 2026 guidelines.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

Martinez Sanchez describes early signs of Parkinson disease, how treatment adapts, and how ambulatory pharmacists fine-tune treatment, adherence, and hope amid new therapies.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.

In a phase 2a trial, the oral NLRP3 inhibitor VTX3232 significantly reduced systemic and liver inflammation markers—including hsCRP and IL-6—independent of weight loss, suggesting a promising new approach to lowering cardiovascular risk in patients with obesity.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention.

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.